Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Satisfaction with pediatric neuropsychological evaluations was surveyed by asking parents or guardians of children who completed pediatric neuropsychological evaluations at a large children's hospital over a 2-year period to complete a 30-item rating scale. The scale included items drawn from published measures of consumer satisfaction, and incorporated a well-validated measure of general satisfaction. A total of 338 surveys were distributed, with 117 completed, for a return rate of 35%. Respondents were generally similar to non-respondents, except that respondents had a higher average level of maternal education and were more likely to have been referred for neuropsychological evaluations by sources outside the hospital. Parents were generally satisfied with pediatric neuropsychological evaluations, although some parents indicated that the evaluations did not provide as much help as expected. A factor analysis of the survey instrument revealed four dimensions of satisfaction: General Satisfaction, Clinician Acceptance/Empathy, Provision of Help, and Facilities/Administrative Assistance. Maternal education was negatively correlated with all four factors, but no other demographic, patient, or clinician variables were significantly related to satisfaction. Future studies could survey physicians and educators to provide a more complete understanding of satisfaction with pediatric neuropsychological evaluations.

Download full-text PDF

Source
http://dx.doi.org/10.1080/13854040600888784DOI Listing

Publication Analysis

Top Keywords

neuropsychological evaluations
24
pediatric neuropsychological
20
satisfaction pediatric
12
satisfaction
8
general satisfaction
8
maternal education
8
evaluations
7
neuropsychological
6
pediatric
5
survey parent
4

Similar Publications

Alzheimer's disease (AD) represents a growing global health burden, underscoring the urgent need for reliable diagnostic and prognostic biomarkers. Although several disease-modifying treatments have recently become available, their effects remain limited, as they primarily delay rather than halt disease progression. Thus, the early and accurate identification of individuals at elevated risk for conversion to AD dementia is crucial to maximize the effectiveness of these therapies and to facilitate timely intervention strategies.

View Article and Find Full Text PDF

Clinical progression on CDR-SB©: Progression-free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations.

Alzheimers Dement

September 2025

Department of Psychiatry and The Behavioral Sciences, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Introduction: Clinical Dementia Rating Sum of Boxes (CDR-SB) is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer's disease (AD) clinical trials. Small CDR-SB differences at the end of a trial often lead to controversy in deriving clinically meaningful interpretations.

Methods: We estimated progression-free time (PFT) participants remained at each 0.

View Article and Find Full Text PDF

Introduction: Digital cognitive assessments offer a promising approach to monitoring cognitive impairments, but repeated use can introduce practice effects, potentially masking changes in cognitive status. We evaluated practice effects using the Defense Automated Neurobehavioral Assessment (DANA), a digital battery designed for cognitive monitoring.

Methods: We analyzed data from 116 participants from the Boston University Alzheimer's Disease Research Center, comparing response times across two DANA sessions, around 90 days apart, while controlling for cognitive status, sex, age, and education.

View Article and Find Full Text PDF

Background: The intestinal microbiota composition has been linked to neurocognitive impairment in people with HIV (PWH). However, the potential interplay of microbial species and related metabolites, particularly in the context of an HIV cure strategy remains underexplored. The BCN02 trial evaluated the impact of romidepsin (RMD), used as a HIV-1 latency reversing agent and with reported beneficial neurological effects, combined with the MVA.

View Article and Find Full Text PDF

Introduction: Adolescence and youth are periods of significant maturational changes, which seem to involve greater susceptibility to disruptive events in the brain, such as binge drinking (BD). This pattern-characterised by repeated episodes of alcohol intoxication-is of particular concern, as it has been associated with significant alterations in the developing brain. Recent evidence indicates that alcohol may also induce changes in gut microbiota composition and that such disturbances can lead to impairments in both brain function and behaviour.

View Article and Find Full Text PDF